XLRN — ACCELERON PHARMA INC
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
As of Q2 2026, 1 SEC-registered investment managers reported holding XLRN (ACCELERON PHARMA INC) in their latest 13F filings, with a combined reported value of $358 across 2 shares. That is +0.0% by share count (+0 shares) versus the previous quarter, while reported value moved +0.0%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Major shareholders of ACCELERON PHARMA INC (XLRN) include T. Rowe Price Associates, Vanguard Group, Farallon Capital Management, ranked by reported 13F value among the 34 institutional holders on this page.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Institutional Ownership by Quarter
| Quarter | Funds holding | Shares | Value | QoQ Net Change |
|---|---|---|---|---|
| Q2 2026 | 1 | 2 | $358 | +0.0% |
| Q1 2026 | 1 | 2 | $358 | +0.0% |
| Q4 2025 | 1 | 2 | $358 | +0.0% |
| Q3 2025 | 1 | 2 | $358 | +0.0% |
| Q2 2025 | 1 | 2 | $358 | +0.0% |
| Q1 2025 | 1 | 2 | $358 | +0.0% |
| Q4 2024 | 1 | 2 | $358 | +0.0% |
| Q3 2024 | 1 | 2 | $358 | +0.0% |
Over the 8 quarters shown, institutional share counts increased 0% in aggregate (Q3 2024 → Q2 2026).
Top Institutional Holders (Q2 2026) — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2 | $358 | 0.00% | Hold |
Holder history for earlier quarters, one table per quarter: Back to the Top 25 holders
Q1 2026 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2 | $358 | 0.00% | Hold |
Q4 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2 | $358 | 0.00% | Hold |
Q3 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2 | $358 | 0.00% | Hold |
Q2 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2 | $358 | 0.00% | Hold |
Q1 2025 — 1 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| 2 | $358 | 0.00% | Hold |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 20 funds)
| Fund | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HUNTINGTON NATIONAL BANK | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | — |
| Northern Trust Corp | — | — | — | — | — | — | — | — | — | — | — | — | 250.12K |
| Wells Fargo & Co | — | — | — | — | — | — | — | — | — | — | — | — | 142.78K |
| Legal & General Investment Management America | — | — | — | — | — | — | — | — | — | — | — | — | 46.45K |
| PNC Financial Services | — | — | — | — | — | — | — | — | — | — | — | — | 6.91K |
| Alkeon Capital Management | — | — | — | — | — | — | — | — | — | — | — | — | 1.25M |
| AQR Capital Management | — | — | — | — | — | — | — | — | — | — | — | — | 2.36K |
| Balyasny Asset Management | — | — | — | — | — | — | — | — | — | — | — | — | 245.49K |
| Bank of America Corp | — | — | — | — | — | — | — | — | — | — | — | — | 282.24K |
| Baron Funds | — | — | — | — | — | — | — | — | — | — | — | — | 1.29M |
| BNY Mellon | — | — | — | — | — | — | — | — | — | — | — | — | 502.90K |
| Citigroup Inc | — | — | — | — | — | — | — | — | — | — | — | — | 248.77K |
| D. E. Shaw & Co | — | — | — | — | — | — | — | — | — | — | — | — | 271.29K |
| Farallon Capital Management | — | — | — | — | — | — | — | — | — | — | — | — | 2.16M |
| Franklin Resources | — | — | — | — | — | — | — | — | — | — | — | — | 399.64K |
| Geode Capital Management | — | — | — | — | — | — | — | — | — | — | — | — | 674.64K |
| Invesco Ltd | — | — | — | — | — | — | — | — | — | — | — | — | 408.81K |
| Marshall Wace | — | — | — | — | — | — | — | — | — | — | — | — | 12.10K |
| Millennium Management | — | — | — | — | — | — | — | — | — | — | — | — | 475.42K |
| Principal Global Investors | — | — | — | — | — | — | — | — | — | — | — | — | 174.80K |
FAQ
Which funds hold XLRN?
As of 2026-Q2, 1 institutional funds reported holding XLRN (ACCELERON PHARMA INC) in SEC 13F filings, with a combined reported value of $358.
How many shares of XLRN do institutions own?
13F filers reported 2 shares of XLRN, worth $358 in aggregate at the end of 2026-Q2.
Is institutional ownership of XLRN rising or falling?
Share counts moved +0.0% versus the prior quarter — accumulation.
Who are the top institutional holders of XLRN?
The largest 13F holders are T. Rowe Price Associates, Vanguard Group, Farallon Capital Management, Fidelity Management & Research (FMR), Janus Henderson Group; the top 25 are ranked at the top of this page.
Who are the major shareholders of ACCELERON PHARMA INC?
The major shareholders of ACCELERON PHARMA INC (XLRN) by reported 13F value are T. Rowe Price Associates, Vanguard Group, Farallon Capital Management, Fidelity Management & Research (FMR), Janus Henderson Group, among 34 institutional holders.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.